Sign in Subscribe
Pharmaceutical industry

Aventis and Millennium Pharmaceuticals Announce $450 Million Biotech Deal

Strategic Insights

— 1 min read

Aventis, a leading European drug company, has signed a massive $450 million deal with biotechnology start-up Millennium Pharmaceuticals, Inc. as part of a comprehensive alliance to develop and commercialize new drugs. Under the agreement, Aventis will acquire a 2% stake in Millennium by purchasing $250 million worth of shares, with the option to buy up to $200 million in technology over the next five years. The two companies will jointly develop innovative therapies for inflammatory diseases, such as rheumatoid arthritis, asthma, and multiple sclerosis, and will work together to accelerate the development of new medicines.

Key Takeaways:

  • The agreement is one of the largest collaborations between a pharmaceutical company and a biotech start-up, valued at $450 million.
  • Aventis will acquire a 2% stake in Millennium by purchasing $250 million worth of shares.
  • The two companies will jointly develop innovative therapies for inflammatory diseases, including rheumatoid arthritis, asthma, and multiple sclerosis.
  • Aventis will also pay up to $200 million over five years to obtain technology for drug development.
  • Millennium will retain its rights to profit from sales and marketing of the developed drugs in the North American market, with Aventis handling the development and marketing outside the region.
  • The alliance aims to create one of the largest inflammatory drug programs in the world, with estimated clinical trials starting in 2-3 years and potential market entry in 7-8 years.
  • Millennium has secured $1.8 billion in revenue from all its partnerships, with the current deal expected to contribute significantly to this total.

Statistics:

  • $450 million: The total value of the deal between Aventis and Millennium Pharmaceuticals.
  • $250 million: The amount Aventis will pay for 2% stake in Millennium.
  • $200 million: The ceiling for Aventis to pay for technology over 5 years.
  • 2%: The percentage stake Aventis will acquire in Millennium through the share purchase.
  • $1.8 billion: The estimated revenue Millennium will generate from all its partnerships.

Sources:

  • Bloomberg News: "Aventis-Biotech Deal Valued at $450 Million" (date not specified)
  • Millennium Pharmaceuticals Inc.: Press Release (date not specified)
  • Robertson Stephens: Analyst Comment (date not specified)
  • Associated Press: "Aventis Takes Bigger Stake in Biotech Firm" (date not specified)

Read more